Mettler-Toledo International (MTD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Achieved strong Q4 and full-year 2025 results with broad-based growth across geographies and product categories, despite challenging market conditions and global trade disputes.
Adjusted EPS grew 8% in Q4 and 4% for the full year; free cash flow conversion was excellent at 99% of adjusted net income.
Demonstrated resilience and agility amid global trade disputes and soft market conditions, maintaining operational excellence and innovation.
Strategic focus on innovation, automation, digitalization, and onshoring positions the company for continued market share gains.
Financial highlights
Q4 2025 reported sales reached $1.13 billion, up 8% year-over-year; local currency sales up 5%.
Q4 adjusted operating profit was $363 million (+3% YoY); adjusted operating margin was 32.1% (down 160 bps YoY).
Q4 adjusted EPS was $13.36 (+8% YoY); reported EPS was $13.98, including discrete tax benefits.
Full-year 2025 net sales grew 4% to $4.03 billion; adjusted EPS up 4% to $42.73.
Free cash flow for 2025 was $878 million, with adjusted free cash flow conversion at 99% of adjusted net income.
Outlook and guidance
2026 local currency sales growth forecast at ~4%; adjusted EPS expected at $46.05–$46.70 (+8–9%).
Q1 2026 guidance: local currency sales up ~3%, adjusted EPS $8.60–$8.75 (+5–7%).
Operating margin expected to rise 60–70 bps (ex-currency); FX to be a 1% sales benefit but slight EPS headwind.
Free cash flow for 2026 expected at ~$900 million; share repurchases planned at $825–$875 million.
Guidance reflects confidence in strategic initiatives and product innovation.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026 - Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026